Clinical trials: Cancer pain

Clinical Pain Management: Practice and Procedures, 2nd edition

Volumn , Issue , 2008, Pages 538-551

  Kongsgaard, Ulf E ^a,b   Werner, Mads U ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71649096724     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13562-44     Document Type: Chapter

References (72)

1. Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. New England Journal of Medicine. 1994; 330: 651-5.
2. Bruera E, Kim HN. Cancer pain. Journal of the American Medical Association. 2003; 290: 2476-9.
3. Zech DF, Grond S, Lynch J et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995; 63: 65-76.
4. Carr DB, Goudas LC, Balk EM et al. Evidence report on the treatment of pain in cancer patients. Journal of the National Cancer Institute Monographs. 2004; 32: 23-31.
5. Bell RF, Wisloff T, Eccleston C, Kalso E. Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer. 2006; 94: 1559-67.
6. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain:new hypotheses derived from studies of opioid infusions. Pain. 1990; 43: 273-86.
7. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Medical Clinics of North America. 2007; 91:199-211.
8. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. Cancer Surveys. 1994; 21: 49-65.
9. Klepstad P, Dale O, Skorpen F et al. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiologica Scandinavica. 2005; 49: 902-08.
10. Stamer UM, Bayerer B, Stuber F. Genetics and variability in opioid response. European Journal of Pain. 2005; 9:101-04.
11. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clinical Pharmacology and Therapeutics. 2007; 81: 429-44.
12. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain:characteristics and impact in patients with cancer pain. Pain. 1999; 81: 129-34.
13. Svendsen KB, Andersen S, Arnason S et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. European Journal of Pain. 2005; 9: 195-206.
14. Caraceni A, Martini C, Zecca E et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliative Medicine. 2004; 18: 177-83.
15. Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: Diurnal pain variation and effects of analgesic therapy. Pain. 2006; 120: 207-12.
16. Donovan-Rodriguez T, Dickenson AH, Urch CE. Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neuroscience Letters. 2004; 360: 29-32.
17. Shimoyama M, Tatsuoka H, Ohtori S et al. Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. Pain. 2005; 114: 221-30.
18. Donovan-Rodriguez T, Dickenson AH, Urch CE. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology. 2005; 102: 132-40.
19. Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005; 117: 450-61.
20. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. Journal of Pain and Symptom Management. 2002; 24: 526-42.
21. Sullivan MJ, Thorn B, Haythornthwaite JA et al. Theoretical perspectives on the relation between catastrophizing and pain. Clinical Journal of Pain. 2001; 17: 52-64.
22. Keefe FJ, Abernethy AP, Campbell C. Psychological approaches to understanding and treating diseaserelated pain. Annual Review of Psychology. 2005; 56:601-30.
23. Farrar JT, Portenoy RK, Berlin JA et al. Defining the clinically important difference in pain outcome measures. Pain. 2000; 88: 287-94.
24. Melzack R, Katz J. Pain assessment in adult patients. In:McMahon SB, Koltzenburg M (eds). Wall and Melzack0s textbook of pain, 5th edn. Philadelphia: Elsevier Churchill Livingstone, 2006: 291-304.
25. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clinical Journal of Pain. 2000; 16: 22-8.
26. Jensen MP, Chen C, Brugger AM. Postsurgical pain outcome assessment. Pain. 2002; 99: 101-09.
27. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975; 1:277-99.
28. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983; 17: 197-210.
29. Fishman B, Pasternak S, Wallenstein SL et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer. 1987; 60: 1151-8.
30. Ramsay M, Winget C, Higginson I. Review: measures to determine the outcome of community services for people with dementia. Age and Ageing. 1995; 24:73-83.
31. Walsh TD. Adjuvant analgesic therapy in cancer pain. In:Foley KM, Bonica JJ, Ventafridda V (eds). Advances in pain research and therapy. New York, NY: Raven Press, 1990:155-69.
32. Hanks G, Cherny NI, Fallon M. Opioid analgesic therapy. In:Doyle D, Hanks G, Cherny N, Calman K (eds). Oxford textbook of palliative medicine, 3rd edn. Oxford: Oxford University Press, 2004: 316-41.
33. Twycross RG. Opioids. In: Wall PD, Melzack R (eds). Textbook of pain, 4th edn. New York: Churchill Livingstone, 1999: 1187-214.
34. Ripamonti C. Pharmacology of opioid analgesia: clinical principles. Cancer pain. In: Bruera ED, Portenoy RK (eds). Assessment and management. Cambridge: Cambridge University Press, 2003: 124-49.
35. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996; 78: 852-7.
36. Dworkin RH, Turk DC, Farrar JT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005; 113: 9-19.
37. Silverman DG, O’Connor TZ, Brull SJ. Integrated assessment of pain scores and rescue morphine use during studies of analgesic efficacy. Anesthesia and Analgesia. 1993; 77: 168-70.
38. Romundstad L, Breivik H, Roald H et al. Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo. Anesthesia and Analgesia. 2006; 102: 418-25.
39. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain and Symptom Management. 1995; 10:378-84.
40. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews. 2004; CD004847.
41. Kaasa S, De Connoy F. Palliative care research. European Journal of Cancer. 2001; 37: S153-9.
42. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002; 359: 248-52.
43. Sacks H, Chalmers TC, Smith Jr H. Randomized versus historical controls for clinical trials. American Journal of Medicine. 1982; 72: 233-40.
44. Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annual Review of Public Health. 1994; 15: 19-38.
45. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research [see comments]. British Medical Journal. 1990; 300: 230-5.
46. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Statistics in Medicine. 2000; 19: 861-77.
47. Caraceni A, Brunelli C, Martini C et al. Cancer pain assessment in clinical trials. A review of the literature (1999-2002). Journal of Pain and Symptom Management. 2005; 29: 507-19.
48. Farrar JT, Young Jr JP, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94: 149-58.
49. Vincent E, Todd S, Whitehead J. A sequential procedure for comparing two experimental treatments with a control. Journal of Biopharmaceutical Statistics. 2002; 12:249-65.
50. Deschamps M, Band PR, Hislop TG et al. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. Journal of Pain and Symptom Management. 1992; 7: 384-92.
51. Parris WC, Johnson Jr BW, Croghan MK et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. Journal of Pain and Symptom Management. 1998; 16: 205-11.
52. Kerr IG. Clinical trials to study pain in patients with advanced cancer: practical difficulties. Anticancer Drugs. 1995; 6: 18-28.
53. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain. 1995; 60: 267-74.
54. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled Clinical Trials. 1998; 19: 178-87.
55. Portenoy RK. Cancer pain general design issues. In: Max M, Portenoy R, Laska R (eds). Advances in pain research and therapy. New York: Raven Press, 1991: 233-66.
56. Bruera E, Schoeller T, Wenk R et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. Journal of Pain and Symptom Management. 1995; 10: 348-55.
57. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer. 1994; 74: 2570-8.
58. MacDonald N, Bruera E. Clinical trials in cancer pain research. In: Foley KM, Bonica JJ, Ventafridda V (eds). Advances in pain research and therapy. New York: Raven Press, 1990: 443-9.
59. Stambaugh JE. Commentary: issues for chronic pain models with specific emphasis on the chronic cancer pain model. In: Max M, Portenoy R, Laska R (eds). Advances in pain research and therapy. New York: Raven Press, 1991:287-9.
60. Kurz A, Sessler DI. Opioid-induced bowel dysfunction:pathophysiology and potential new therapies. Drugs. 2003; 63: 649-71.
61. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet. 2001; 357: 1311-15.
62. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. European Journal of Pain. 1998; 2: 53-62.
63. Stambaugh Jr JE, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clinical Pharmacology and Therapeutics. 1988; 44: 665-9.
64. Moher D, Schulz KF, Altman DG. The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine. 2001; 134: 657-62.
65. Syrjala KL, Donaldson GW, Davis MW et al. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain. 1995; 63: 189-98.
66. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine. 2001; 344:1594-602.
67. Zelen M. A new design for randomized clinical trials. New England Journal of Medicine. 1979; 300:1242-5.
68. Lavelle-Jones C, Byrne DJ, Rice P, Cuschieri A. Factors affecting quality of informed consent. British Medical Journal. 1993; 306: 885-90.
69. Joffe S, Cook EF, Cleary PD et al. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001; 358: 1772-7.
70. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Social Science and Medicine. 1997; 45:1337-55.
71. Casarett DJ, Karlawish JH. Are special ethical guidelines needed for palliative care research? Journal of Pain and Symptom Management. 2000; 20: 130-9.
72. Rivera R, Borasky D, Rice R et al. Informed consent: an international researchers’ perspective. American Journal of Public Health. 2007; 97: 25-30.